Swedish Orphan Biovitrum AB (publ) (SOBI)
Stockholm Exchange · Sweden · prices in SEK · close of 22 Oct 2026
Key indicators
| Last close | SEK 452.00 |
|---|---|
| 52-week range | 310.60 – 487.00 |
| Return, 1 month / 3 months | +0.8% / −2.4% |
| Return, 1 year / 3 years | +43.0% / +116.3% |
| Trend | Uptrend |
| RSI (14) | 57 |
| Volatility (1 year) | 27.5% |
| Worst drawdown (1 year) | -14.6% |
| Average daily value traded | 131.07M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Swedish Orphan Biovitrum, often called Sobi, is a pharmaceutical company based in Stockholm, Sweden. It develops and supplies medicines for rare diseases, concentrating on haematology, immunology and specialty care. Its products include enzyme replacement therapies and treatments for bleeding disorders and other rare conditions. The company serves patients, hospitals and healthcare professionals through its own operations and partners in markets across Europe, North America and other regions of the world.
On this site Swedish Orphan Biovitrum AB (publ) appears as a stock on the Stockholm Exchange (Sweden), code SOBI, with prices in Swedish kronor (SEK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Swedish Orphan Biovitrum AB (publ) (SOBI) trades on the Stockholm Exchange in Sweden. It last closed at SEK 452.00 on 22 October 2026.
Its price-based Market X-Ray is 84 out of 100 (a strong price profile), ranking 17 of 912 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 43.0% and over the last three months it fell 2.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Stockholm Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 80 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 6.9% | ||
| From 52-week high | -5.8% | ||
| Momentum | 73 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | -2.4% | ||
| 6-month return | 11.3% | ||
| 12-month return, skipping the last month | 41.8% | ||
| Stability (higher is calmer) | 91 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 27.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -14.6% | ||
| Liquidity | 96 · Strong | Trades actively. | |
| Average daily value traded | 131.07M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +2.4% |
|---|---|
| 1 month | +0.8% |
| 3 months | −2.4% |
| 6 months | +11.3% |
| 1 year | +43.0% |
| 3 years | +116.3% |
| 5 years | +101.4% |
Signals
| 50-day / 200-day average | 445.68 / 422.83 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 10.58 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Stockholm Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.